HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus.

Abstract
A multicenter, longitudinal study of children below the age of 16 years with newly diagnosed Type 1 (insulin-dependent) diabetes treated either with porcine monocomponent insulin (n = 26) or semisynthetic human monocomponent insulin (n = 26) was performed during the first 24 months after onset of diabetes. The two groups were carefully matched for age, duration of disease symptoms, initial metabolic values, islet cell antibodies and HLA-DR antigens. During the 24-month observation period there was no significant difference between the two groups in respect to the clinical course, insulin dosage, HbA1 and residual B-cell activity. No child in either group had a real remission without necessitating insulin therapy. The prevalence of insulin antibodies increased slowly and was 62% in the group treated by human insulin and 52% in the porcine insulin-treated group after 24 months. The titres were generally low and there was no statistical difference between the two groups in respect to insulin antibody formation.
AuthorsK Zuppinger, C Aebi, S Fankhauser, G Herz, R P Zurbrügg, K Schopfer, T M Neri
JournalDiabetologia (Diabetologia) Vol. 30 Issue 12 Pg. 912-5 (Dec 1987) ISSN: 0012-186X [Print] Germany
PMID3325323 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Glycated Hemoglobin A
  • HLA-DR Antigens
  • Insulin
  • Insulin Antibodies
Topics
  • Antibody Formation (drug effects)
  • Child
  • Diabetes Mellitus, Type 1 (drug therapy)
  • Female
  • Glycated Hemoglobin (analysis)
  • HLA-DR Antigens (immunology)
  • Humans
  • Insulin (therapeutic use)
  • Insulin Antibodies (analysis)
  • Longitudinal Studies
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: